Biogen develops and sells therapies for neurological, neurodegenerative, and rare diseases. Its treatments include multiple sclerosis medicines, spinal muscular atrophy therapy, and Alzheimer's disease-related products and partnerships. The company invests in neuroscience research and commercialization, with performance influenced by product competition, clinical results, and specialist treatment adoption.
Biogen Inc. (BIIB) has a MarketKingdoms composite score of 65.9 (B), an B-range rating. It ranks 723rd of 1,866 covered companies, 32nd of 78 in Healthcare (sector average 64.4) and 5th of 13 in Drug Manufacturers - General. Scores as of 2026-10-26.
Its strongest lenses are Trend (momentum) at 83 (Healthcare average 50) and Industry opportunity at 81 (Healthcare average 81). Its weakest lenses are Expansion (growth) at 30 (sector average 50) and Quality (profitability) at 49 (sector average 50).
| Lens | Type | BIIB | Healthcare average | Drug Manufacturers - General average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 81 | 81 | 81 | 65th |
| Stock selection | Research signal | 81 | 79 | 78 | 59th |
| KPI momentum | Research signal | 79 | 78 | 77 | 51st |
| Catalyst watch | Research signal | 81 | 74 | 71 | 97th |
| Price (valuation) | Fundamental lens | 50 | 50 | 53 | 49th |
| Expansion (growth) | Fundamental lens | 30 | 50 | 39 | 17th |
| Quality (profitability) | Fundamental lens | 49 | 50 | 60 | 56th |
| Trend (momentum) | Fundamental lens | 83 | 50 | 55 | 94th |
The most recent call analysed was held on 2026-07-29 (fiscal 2026 Q2). After it the composite moved from 81.6 to 80.9. MarketKingdoms checks what management promised on each call against what it later delivered.
The composite at the time of each event; today's composite is 65.9.
The stock's valuation gap is +31.0%: its price is well above the path its market, sector and industry moves explain (the model reads it as strongly overvalued versus that path). Factor sensitivity: market beta 1.44, sector beta 0.59, industry beta 0.50; the factor model explains 51% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Amgen Inc. (AMGN) | 71.9 | B+ | +13.9% |
| Eli Lilly & Co. (LLY) | 71.2 | B+ | +1.7% |
| AbbVie Inc. (ABBV) | 69.0 | B | -3.2% |
| Bristol-Myers Squibb Co. (BMY) | 66.3 | B | -11.0% |
| Gilead Sciences Inc. (GILD) | 65.5 | B | -3.5% |
| GSK plc ADR (GSK) | 63.0 | B- | -5.1% |
| Novo Nordisk ADR (NVO) | 62.9 | B- | -24.0% |
| Novartis AG ADR (NVS) | 62.1 | B- | -3.9% |
Biogen Inc. financial statements · Healthcare sector ranking · Drug Manufacturers - General industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.